Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
Hookipa Pharma (HOOK) Stock Price & Analysis
331 Followers
HOOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.52 - $2.05
Previous Close$0.52
Volume584.60K
Average Volume (3M)384.26K
Market Cap
$42.65M
Enterprise Value-$88.66M
Total Cash (Recent Filing)$135.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)-0.5
Beta0.87
Next Earnings
Nov 15, 2023EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding83,950,107
10 Day Avg. Volume210,962
30 Day Avg. Volume384,258
Standard Deviation0.21
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.40
Price to Sales (P/S)15.92
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.57
Enterprise Value/Gross Profit-6.22
Enterprise Value/Ebitda1.33
Forecast
1Y Price Target
$6.83Price Target Upside1191.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Hookipa Pharma News
Press ReleasesHOOKIPA Announces Executive Leadership Change
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $0.52 and its highest was $2.05 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Currently, no data Available
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is Nov 15, 2023 which is in 27 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Aug 10, 2023. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.012.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -$0.21.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 81,550,590 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Among the largest hedge funds holding Hookipa Pharma Inc’s share is Baker Bros Advisors LP. It holds Hookipa Pharma Inc’s shares valued at 4M.
---
Hookipa Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (1191.12% Upside)
$6.83 (1191.12% Upside)
Hedge Fund Trend
Increased
By 950.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.29%
12-Months-Change
Fundamentals
Return on Equity
-55.91%
Trailing 12-Months
Asset Growth
10.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
Top 5 ETFs holding HOOK
Vanguard Total Stock Market ETF
$860.02K
Up to five ETFs with an Outperform Smart Score that hold HOOK. The ETFs are listed according to market value of HOOK within the ETF
---